Cutting-Edge Approaches to Obesity Management: The Latest Pharmacological Options.

Katherine H Saunders, Louis J Aronne, Sarah H Schmitz

Journal: Endocrinology and metabolism clinics of North America 2025;54(1):85-102

PMID: 39919879

Full Text on Elsevier Science View on PubMed

Abstract

Successful treatment of obesity requires a multidisciplinary approach including dietary strategy, physical activity, and behavioral modification. The seven FDA-approved anti-obesity medications are phentermine, orlistat, phentermine/topiramate ER, naltrexone SR/bupropion SR, liraglutide 3.0 mg, semaglutide 2.4 mg, and tirzepatide. Obesity is a chronic disease and these medications should be prescribed with the intention of long-term use. In this article, we summarize data from phase 3 clinical trials which led to drug approval, and we review the clinical indications, mechanism of action, dosing/administration, side effects, drug interactions and contraindications for each medication.

Address: Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine, New York, NY 10021, USA. Electronic address: [email protected].; Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine, New York, NY 10021, USA.

DOI: 10.1016/j.ecl.2024.09.003

Link outs

Free resources

Medical:

https://medlineplus.gov/obesity.html

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-SNCG-3

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Anti-Obesity Agents, Obesity, Naltrexone, Obesity Management, Phentermine, Bupropion